Type 2 Diabetes - Pipeline Review, H1 2014
出 版 商：Global Markets Direct
出版日期：2014/02/28
頁 數：1,052頁
文件格式：PDF
價 格：
USD 2,500 (Single-User License)
USD 5,000 (Multi-User License)
USD 7,500 (Global-User License)
USD 5,000 (Multi-User License)
USD 7,500 (Global-User License)
Type 2 Diabetes - Pipeline Review, H1 2014
Summary
Global Markets Direct’s, ‘Type 2 Diabetes - Pipeline Review, H1 2014’, provides an overview of the Type 2 Diabetes’s therapeutic pipeline.
This report provides comprehensive information on the therapeutic development for Type 2 Diabetes, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Type 2 Diabetes and special features on late-stage and discontinued projects.
Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.
The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.
Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.
Scope
- The report provides a snapshot of the global therapeutic landscape of Type 2 Diabetes
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in the therapeutics development for Type 2 Diabetes and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects
- A review of the Type 2 Diabetes products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Type 2 Diabetes pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products
Reasons to buy
- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for Type 2 Diabetes
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding Type 2 Diabetes pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Summary
Global Markets Direct’s, ‘Type 2 Diabetes - Pipeline Review, H1 2014’, provides an overview of the Type 2 Diabetes’s therapeutic pipeline.
This report provides comprehensive information on the therapeutic development for Type 2 Diabetes, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Type 2 Diabetes and special features on late-stage and discontinued projects.
Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.
The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.
Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.
Scope
- The report provides a snapshot of the global therapeutic landscape of Type 2 Diabetes
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in the therapeutics development for Type 2 Diabetes and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects
- A review of the Type 2 Diabetes products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Type 2 Diabetes pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products
Reasons to buy
- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for Type 2 Diabetes
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding Type 2 Diabetes pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Table of Contents
Table of Contents 2
Introduction 9
Type 2 Diabetes Overview 10
Therapeutics Development 11
Type 2 Diabetes - Therapeutics under Development by Companies 13
Type 2 Diabetes - Therapeutics under Investigation by Universities/Institutes 28
Type 2 Diabetes - Pipeline Products Glance 31
Type 2 Diabetes - Products under Development by Companies 35
Type 2 Diabetes - Products under Investigation by Universities/Institutes 63
Type 2 Diabetes - Companies Involved in Therapeutics Development 65
Type 2 Diabetes - Therapeutics Assessment 241
Drug Profiles 268
Type 2 Diabetes - Recent Pipeline Updates 883
Type 2 Diabetes - Dormant Projects 985
Type 2 Diabetes - Discontinued Products 991
Type 2 Diabetes - Product Development Milestones 995
Appendix 1002
List of Tables
Number of Products under Development for Type 2 Diabetes, H1 2014 60
Number of Products under Development for Type 2 Diabetes - Comparative Analysis, H1 2014 61
Number of Products under Development by Companies, H1 2014 63
Number of Products under Development by Companies, H1 2014 (Contd..1) 64
Number of Products under Development by Companies, H1 2014 (Contd..2) 65
Number of Products under Development by Companies, H1 2014 (Contd..3) 66
Number of Products under Development by Companies, H1 2014 (Contd..4) 67
Number of Products under Development by Companies, H1 2014 (Contd..5) 68
Number of Products under Development by Companies, H1 2014 (Contd..6) 69
Number of Products under Development by Companies, H1 2014 (Contd..7) 70
Number of Products under Development by Companies, H1 2014 (Contd..8) 71
Number of Products under Development by Companies, H1 2014 (Contd..9) 72
Number of Products under Development by Companies, H1 2014 (Contd..10) 73
Number of Products under Development by Companies, H1 2014 (Contd..11) 74
Number of Products under Development by Companies, H1 2014 (Contd..12) 75
Number of Products under Development by Companies, H1 2014 (Contd..13) 76
Number of Products under Investigation by Universities/Institutes, H1 2014 78
Number of Products under Investigation by Universities/Institutes, H1 2014 (Contd..1) 79
Comparative Analysis by Late Stage Development, H1 2014 80
Comparative Analysis by Clinical Stage Development, H1 2014 81
Comparative Analysis by Early Stage Development, H1 2014 82
Comparative Analysis by Unknown Stage Development, H1 2014 83
Products under Development by Companies, H1 2014 84
Products under Development by Companies, H1 2014 (Contd..1) 85
Products under Development by Companies, H1 2014 (Contd..2) 86
Products under Development by Companies, H1 2014 (Contd..3) 87
Products under Development by Companies, H1 2014 (Contd..4) 88
Products under Development by Companies, H1 2014 (Contd..5) 89
Products under Development by Companies, H1 2014 (Contd..6) 90
Products under Development by Companies, H1 2014 (Contd..7) 91
Products under Development by Companies, H1 2014 (Contd..8) 92
Products under Development by Companies, H1 2014 (Contd..9) 93
Products under Development by Companies, H1 2014 (Contd..10) 94
Products under Development by Companies, H1 2014 (Contd..11) 95
Products under Development by Companies, H1 2014 (Contd..12) 96
Products under Development by Companies, H1 2014 (Contd..13) 97
Products under Development by Companies, H1 2014 (Contd..14) 98
Products under Development by Companies, H1 2014 (Contd..15) 99
Products under Development by Companies, H1 2014 (Contd..16) 100
Products under Development by Companies, H1 2014 (Contd..17) 101
Products under Development by Companies, H1 2014 (Contd..18) 102
Products under Development by Companies, H1 2014 (Contd..19) 103
Products under Development by Companies, H1 2014 (Contd..20) 104
Products under Development by Companies, H1 2014 (Contd..21) 105
Products under Development by Companies, H1 2014 (Contd..22) 106
Products under Development by Companies, H1 2014 (Contd..23) 107
Products under Development by Companies, H1 2014 (Contd..24) 108
Products under Development by Companies, H1 2014 (Contd..25) 109
Products under Development by Companies, H1 2014 (Contd..26) 110
Products under Development by Companies, H1 2014 (Contd..27) 111
Products under Investigation by Universities/Institutes, H1 2014 112
Products under Investigation by Universities/Institutes, H1 2014 (Contd..1) 113
Type 2 Diabetes - Pipeline by Bristol-Myers Squibb Company, H1 2014 114
Type 2 Diabetes - Pipeline by Johnson & Johnson, H1 2014 115
Type 2 Diabetes - Pipeline by Boehringer Ingelheim GmbH, H1 2014 116
Type 2 Diabetes - Pipeline by F. Hoffmann-La Roche Ltd., H1 2014 117
Type 2 Diabetes - Pipeline by Shionogi & Co., Ltd., H1 2014 118
Type 2 Diabetes - Pipeline by Amgen Inc., H1 2014 119
Type 2 Diabetes - Pipeline by Sanofi, H1 2014 120
Type 2 Diabetes - Pipeline by AstraZeneca PLC, H1 2014 121
Type 2 Diabetes - Pipeline by Eli Lilly and Company, H1 2014 122
Type 2 Diabetes - Pipeline by GlaxoSmithKline plc, H1 2014 123
Type 2 Diabetes - Pipeline by MedImmune, LLC, H1 2014 124
Type 2 Diabetes - Pipeline by Isis Pharmaceuticals, Inc., H1 2014 125
Type 2 Diabetes - Pipeline by Gilead Sciences, Inc., H1 2014 126
Type 2 Diabetes - Pipeline by Daiichi Sankyo Company, Limited, H1 2014 127
Type 2 Diabetes - Pipeline by Merck & Co., Inc., H1 2014 128
Type 2 Diabetes - Pipeline by Dainippon Sumitomo Pharma Co., Ltd., H1 2014 129
Type 2 Diabetes - Pipeline by Taisho Pharmaceutical Co., Ltd., H1 2014 130
Type 2 Diabetes - Pipeline by Euroscreen S.A., H1 2014 131
Type 2 Diabetes - Pipeline by Novo Nordisk A/S, H1 2014 132
Type 2 Diabetes - Pipeline by Generex Biotechnology Corporation, H1 2014 133
Type 2 Diabetes - Pipeline by Takeda Pharmaceutical Company Limited, H1 2014 134
Type 2 Diabetes - Pipeline by FibroGen, Inc., H1 2014 135
Type 2 Diabetes - Pipeline by Ipsen S.A., H1 2014 136
Type 2 Diabetes - Pipeline by Piramal Enterprises Limited, H1 2014 137
Type 2 Diabetes - Pipeline by Neurocrine Biosciences, Inc., H1 2014 138
Type 2 Diabetes - Pipeline by Teijin Pharma Limited, H1 2014 139
Type 2 Diabetes - Pipeline by Novartis AG, H1 2014 140
Type 2 Diabetes - Pipeline by Astellas Pharma Inc., H1 2014 141
Type 2 Diabetes - Pipeline by Chugai Pharmaceutical Co., Ltd., H1 2014 142
Type 2 Diabetes - Pipeline by Forest Laboratories, Inc., H1 2014 143
Type 2 Diabetes - Pipeline by Glenmark Pharmaceuticals Ltd., H1 2014 144
Type 2 Diabetes - Pipeline by Japan Tobacco Inc., H1 2014 145
Type 2 Diabetes - Pipeline by Kissei Pharmaceutical Co., Ltd., H1 2014 146
Type 2 Diabetes - Pipeline by Les Laboratoires Servier SAS, H1 2014 147
Type 2 Diabetes - Pipeline by Mitsubishi Tanabe Pharma Corporation, H1 2014 148
Type 2 Diabetes - Pipeline by Pfizer Inc., H1 2014 149
Type 2 Diabetes - Pipeline by Ranbaxy Laboratories Limited, H1 2014 150
Type 2 Diabetes - Pipeline by Zydus Cadila Healthcare Limited, H1 2014 151
Type 2 Diabetes - Pipeline by Hadasit Medical Research Services & Development Ltd, H1 2014 152
Type 2 Diabetes - Pipeline by Biodel Inc., H1 2014 153
Type 2 Diabetes - Pipeline by Bayer AG, H1 2014 154
Type 2 Diabetes - Pipeline by OPKO Health, Inc., H1 2014 155
Type 2 Diabetes - Pipeline by MannKind Corporation, H1 2014 156
Type 2 Diabetes - Pipeline by Halozyme Therapeutics, Inc., H1 2014 157
Type 2 Diabetes - Pipeline by Toray Industries, Inc., H1 2014 158
Type 2 Diabetes - Pipeline by Merck KGaA, H1 2014 159
Type 2 Diabetes - Pipeline by Alchemia Limited, H1 2014 160
Type 2 Diabetes - Pipeline by Addex Therapeutics, H1 2014 161
Type 2 Diabetes - Pipeline by Evotec AG, H1 2014 162
Type 2 Diabetes - Pipeline by AlbireoPharma, H1 2014 163
Type 2 Diabetes - Pipeline by GW Pharmaceuticals plc, H1 2014 164
Type 2 Diabetes - Pipeline by Harbor Therapeutics, Inc., H1 2014 165
Type 2 Diabetes - Pipeline by Enzo Biochem, Inc., H1 2014 166
Type 2 Diabetes - Pipeline by Genfit SA, H1 2014 167
Type 2 Diabetes - Pipeline by Ligand Pharmaceuticals, Inc., H1 2014 168
Type 2 Diabetes - Pipeline by Mesoblast Limited, H1 2014 169
Type 2 Diabetes - Pipeline by Oramed Pharmaceuticals, Inc., H1 2014 170
Type 2 Diabetes - Pipeline by Orchid Chemicals & Pharmaceuticals Ltd, H1 2014 171
Type 2 Diabetes - Pipeline by ConjuChem Biotechnologies Inc., H1 2014 172
Type 2 Diabetes - Pipeline by Lexicon Pharmaceuticals, Inc., H1 2014 173
Type 2 Diabetes - Pipeline by Arena Pharmaceuticals, Inc., H1 2014 174
Type 2 Diabetes - Pipeline by Flamel Technologies S.A., H1 2014 175
Type 2 Diabetes - Pipeline by CSL Limited, H1 2014 176
Type 2 Diabetes - Pipeline by ProteoTech, Inc., H1 2014 177
Type 2 Diabetes - Pipeline by Sanwa Kagaku Kenkyusho Co., Ltd., H1 2014 178
Type 2 Diabetes - Pipeline by Yuhan Corporation, H1 2014 179
Type 2 Diabetes - Pipeline by XOMA Corporation, H1 2014 180
Type 2 Diabetes - Pipeline by Immuron Limited, H1 2014 181
Type 2 Diabetes - Pipeline by IPCA Laboratories Limited, H1 2014 182
Type 2 Diabetes - Pipeline by Xenetic Biosciences plc, H1 2014 183
Type 2 Diabetes - Pipeline by Handok Inc., H1 2014 184
Type 2 Diabetes - Pipeline by Hyundai Pharmaceutical Co., Ltd., H1 2014 185
Type 2 Diabetes - Pipeline by LG Life Sciences, Ltd., H1 2014 186
Type 2 Diabetes - Pipeline by Transition Therapeutics Inc., H1 2014 187
Type 2 Diabetes - Pipeline by Jiangsu Hengrui Medicine Co., Ltd., H1 2014 188
Type 2 Diabetes - Pipeline by Uni-Bio Science Group Ltd., H1 2014 189
Type 2 Diabetes - Pipeline by Panacea Biotec Limited, H1 2014 190
Type 2 Diabetes - Pipeline by Summit Corporation plc, H1 2014 191
Type 2 Diabetes - Pipeline by Phynova Group Ltd, H1 2014 192
Type 2 Diabetes - Pipeline by Genovate Biotechnology Co., LTD., H1 2014 193
Type 2 Diabetes - Pipeline by DiaMedica Inc., H1 2014 194
Type 2 Diabetes - Pipeline by NeuroVive Pharmaceutical AB, H1 2014 195
Type 2 Diabetes - Pipeline by Angelini Group, H1 2014 196
Type 2 Diabetes - Pipeline by Debiopharm International S.A., H1 2014 197
Type 2 Diabetes - Pipeline by Advinus Therapeutics Ltd., H1 2014 198
Type 2 Diabetes - Pipeline by CJ CheilJedang Corp., H1 2014 199
Type 2 Diabetes - Pipeline by Chipscreen Biosciences Ltd, H1 2014 200
Type 2 Diabetes - Pipeline by Aurigene Discovery Technologies Limited, H1 2014 201
Type 2 Diabetes - Pipeline by ActogeniX NV, H1 2014 202
Type 2 Diabetes - Pipeline by Camurus AB, H1 2014 203
Type 2 Diabetes - Pipeline by Jenrin Discovery, Inc., H1 2014 204
Type 2 Diabetes - Pipeline by reMYND, H1 2014 205
Type 2 Diabetes - Pipeline by Wellstat Therapeutics Corporation, H1 2014 206
Type 2 Diabetes - Pipeline by Celon Pharma Sp. z o.o., H1 2014 207
Type 2 Diabetes - Pipeline by Cortendo Invest AB, H1 2014 208
Type 2 Diabetes - Pipeline by Anchor Therapeutics, Inc., H1 2014 209
Type 2 Diabetes - Pipeline by Arisaph Pharmaceuticals, Inc., H1 2014 210
Type 2 Diabetes - Pipeline by Protemix Corporation Limited, H1 2014 211
Type 2 Diabetes - Pipeline by Allozyne, Inc., H1 2014 212
Type 2 Diabetes - Pipeline by Metabolic Solutions Development Co., H1 2014 213
Type 2 Diabetes - Pipeline by Zafgen Inc., H1 2014 214
Type 2 Diabetes - Pipeline by Catabasis Pharmaceuticals, Inc., H1 2014 215
Type 2 Diabetes - Pipeline by PhaseBio Pharmaceuticals, Inc., H1 2014 216
Type 2 Diabetes - Pipeline by Melior Discovery, Inc., H1 2014 217
Type 2 Diabetes - Pipeline by Diabetology Limited, H1 2014 218
Type 2 Diabetes - Pipeline by Braasch Biotech LLC, H1 2014 219
Type 2 Diabetes - Pipeline by Zealand Pharma A/S, H1 2014 220
Type 2 Diabetes - Pipeline by Intarcia Therapeutics, Inc., H1 2014 221
Type 2 Diabetes - Pipeline by Theracos, Inc., H1 2014 222
Type 2 Diabetes - Pipeline by Versartis, Inc., H1 2014 223
Type 2 Diabetes - Pipeline by Kainos Medicine, Inc., H1 2014 224
Type 2 Diabetes - Pipeline by Nordic Bioscience a/s, H1 2014 225
Type 2 Diabetes - Pipeline by InteKrin Therapeutics, Inc., H1 2014 226
Type 2 Diabetes - Pipeline by Virobay Inc., H1 2014 227
Type 2 Diabetes - Pipeline by Noxxon Pharma AG, H1 2014 228
Type 2 Diabetes - Pipeline by Avaxia Biologics, Inc., H1 2014 229
Type 2 Diabetes - Pipeline by Intercept Pharmaceuticals, Inc., H1 2014 230
Type 2 Diabetes - Pipeline by Omeros Corporation, H1 2014 231
Type 2 Diabetes - Pipeline by TransTech Pharma, Inc., H1 2014 232
Type 2 Diabetes - Pipeline by Bridge Bioresearch Plc, H1 2014 233
Type 2 Diabetes - Pipeline by Synthetic Biologics, Inc., H1 2014 234
Type 2 Diabetes - Pipeline by Targacept, Inc., H1 2014 235
Type 2 Diabetes - Pipeline by N-Gene Research Laboratories, Inc., H1 2014 236
Type 2 Diabetes - Pipeline by Obio Pharmaceutical Holdings Limited, H1 2014 237
Type 2 Diabetes - Pipeline by ChemoCentryx, Inc., H1 2014 238
Type 2 Diabetes - Pipeline by USV Limited, H1 2014 239
Type 2 Diabetes - Pipeline by Vitae Pharmaceuticals, Inc., H1 2014 240
Type 2 Diabetes - Pipeline by CureDM, Inc., H1 2014 241
Type 2 Diabetes - Pipeline by Verva Pharmaceuticals Limited, H1 2014 242
Type 2 Diabetes - Pipeline by Exsulin Corporation, H1 2014 243
Type 2 Diabetes - Pipeline by Medestea Research & Production S.p.A., H1 2014 244
Type 2 Diabetes - Pipeline by NasVax Ltd., H1 2014 245
Type 2 Diabetes - Pipeline by Stelic Institute & Co., H1 2014 246
Type 2 Diabetes - Pipeline by Vybion, Inc., H1 2014 247
Type 2 Diabetes - Pipeline by Regulus Therapeutics Inc., H1 2014 248
Type 2 Diabetes - Pipeline by Esperion Therapeutics, Inc., H1 2014 249
Type 2 Diabetes - Pipeline by Sihuan Pharmaceutical Holdings Group Ltd., H1 2014 250
Type 2 Diabetes - Pipeline by NGM Biopharmaceuticals, Inc., H1 2014 251
Type 2 Diabetes - Pipeline by Alize Pharma SAS, H1 2014 252
Type 2 Diabetes - Pipeline by Ardelyx, Inc., H1 2014 253
Type 2 Diabetes - Pipeline by Heptares Therapeutics Ltd., H1 2014 254
Type 2 Diabetes - Pipeline by Mitsubishi Pharmaceutical Corporation, H1 2014 255
Type 2 Diabetes - Pipeline by Receptos, Inc., H1 2014 256
Type 2 Diabetes - Pipeline by MicroDose Therapeutx, Inc., H1 2014 257
Type 2 Diabetes - Pipeline by Sirona Biochem Corp, H1 2014 258
Type 2 Diabetes - Pipeline by XBiotech USA, Inc., H1 2014 259
Type 2 Diabetes - Pipeline by Carmot Therapeutics, Inc., H1 2014 260
Type 2 Diabetes - Pipeline by Connexios Life Sciences Pvt. Ltd., H1 2014 261
Type 2 Diabetes - Pipeline by Serometrix, LLC, H1 2014 262
Type 2 Diabetes - Pipeline by PharmaIN Corporation, H1 2014 263
Type 2 Diabetes - Pipeline by Stempeutics Research Private Limited, H1 2014 264
Type 2 Diabetes - Pipeline by Serodus ASA, H1 2014 265
Type 2 Diabetes - Pipeline by SignPath Pharma Inc, H1 2014 266
Type 2 Diabetes - Pipeline by Elcelyx Therapeutics, Inc., H1 2014 267
Type 2 Diabetes - Pipeline by Thermalin Diabetes Inc., H1 2014 268
Type 2 Diabetes - Pipeline by Selvita S.A, H1 2014 269
Type 2 Diabetes - Pipeline by Poxel SA, H1 2014 270
Type 2 Diabetes - Pipeline by Medesis Pharma S.A., H1 2014 271
Type 2 Diabetes - Pipeline by Kadmon Pharmaceuticals, LLC, H1 2014 272
Type 2 Diabetes - Pipeline by Neopharm Co., Ltd., H1 2014 273
Type 2 Diabetes - Pipeline by Shanghai Pharmaceuticals Holding Co Ltd, H1 2014 274
Type 2 Diabetes - Pipeline by Hanmi Pharmaceuticals, Co. Ltd., H1 2014 275
Type 2 Diabetes - Pipeline by Metabolys S.A.S., H1 2014 276
Type 2 Diabetes - Pipeline by Boston Therapeutics, Inc., H1 2014 277
Type 2 Diabetes - Pipeline by Cardiolynx AG, H1 2014 278
Type 2 Diabetes - Pipeline by TWi Pharmaceuticals, Inc., H1 2014 279
Type 2 Diabetes - Pipeline by Allinky Biopharma, H1 2014 280
Type 2 Diabetes - Pipeline by Rhizen Pharmaceuticals SA, H1 2014 281
Type 2 Diabetes - Pipeline by Hua Medicine Ltd., H1 2014 282
Type 2 Diabetes - Pipeline by Curaxys, S.L., H1 2014 283
Type 2 Diabetes - Pipeline by MidaSol Therapeutics LP, H1 2014 284
Type 2 Diabetes - Pipeline by Foresee Pharmaceuticals, LLC, H1 2014 285
Type 2 Diabetes - Pipeline by Paras Biopharmaceuticals Finland Oy, H1 2014 286
Type 2 Diabetes - Pipeline by CymaBay Therapeutics, Inc., H1 2014 287
Type 2 Diabetes - Pipeline by Biospherics.net Incorporated, H1 2014 288
Type 2 Diabetes - Pipeline by Dong-A Socio Holdings Co Ltd, H1 2014 289
Assessment by Monotherapy Products, H1 2014 290
Assessment by Combination Products, H1 2014 291
Number of Products by Stage and Target, H1 2014 294
Number of Products by Stage and Mechanism of Action, H1 2014 303
Number of Products by Stage and Route of Administration, H1 2014 313
Number of Products by Stage and Molecule Type, H1 2014 316
Type 2 Diabetes Therapeutics - Recent Pipeline Updates, H1 2014 932
Type 2 Diabetes - Dormant Projects, H1 2014 1034
Type 2 Diabetes - Discontinued Products, H1 2014 1040
List of Figures
Number of Products under Development for Type 2 Diabetes, H1 2014 60
Number of Products under Development for Type 2 Diabetes - Comparative Analysis, H1 2014 61
Number of Products under Development by Companies, H1 2014 62
Number of Products under Investigation by Universities/Institutes, H1 2014 77
Comparative Analysis by Late Stage Development, H1 2014 80
Comparative Analysis by Clinical Stage Development, H1 2014 81
Comparative Analysis by Early Stage Products, H1 2014 82
Assessment by Monotherapy Products, H1 2014 290
Assessment by Combination Products, H1 2014 291
Number of Products by Top 10 Target, H1 2014 292
Number of Products by Stage and Top 10 Target, H1 2014 293
Number of Products by Top 10 Mechanism of Action, H1 2014 301
Number of Products by Stage and Top 10 Mechanism of Action, H1 2014 302
Number of Products by Top 10 Route of Administration, H1 2014 311
Number of Products by Stage and Top 10 Route of Administration, H1 2014 312
Number of Products by Top 10 Molecule Type, H1 2014 314
Number of Products by Stage and Top 10 Molecule Type, H1 2014 315
Table of Contents 2
Introduction 9
Type 2 Diabetes Overview 10
Therapeutics Development 11
Type 2 Diabetes - Therapeutics under Development by Companies 13
Type 2 Diabetes - Therapeutics under Investigation by Universities/Institutes 28
Type 2 Diabetes - Pipeline Products Glance 31
Type 2 Diabetes - Products under Development by Companies 35
Type 2 Diabetes - Products under Investigation by Universities/Institutes 63
Type 2 Diabetes - Companies Involved in Therapeutics Development 65
Type 2 Diabetes - Therapeutics Assessment 241
Drug Profiles 268
Type 2 Diabetes - Recent Pipeline Updates 883
Type 2 Diabetes - Dormant Projects 985
Type 2 Diabetes - Discontinued Products 991
Type 2 Diabetes - Product Development Milestones 995
Appendix 1002
List of Tables
Number of Products under Development for Type 2 Diabetes, H1 2014 60
Number of Products under Development for Type 2 Diabetes - Comparative Analysis, H1 2014 61
Number of Products under Development by Companies, H1 2014 63
Number of Products under Development by Companies, H1 2014 (Contd..1) 64
Number of Products under Development by Companies, H1 2014 (Contd..2) 65
Number of Products under Development by Companies, H1 2014 (Contd..3) 66
Number of Products under Development by Companies, H1 2014 (Contd..4) 67
Number of Products under Development by Companies, H1 2014 (Contd..5) 68
Number of Products under Development by Companies, H1 2014 (Contd..6) 69
Number of Products under Development by Companies, H1 2014 (Contd..7) 70
Number of Products under Development by Companies, H1 2014 (Contd..8) 71
Number of Products under Development by Companies, H1 2014 (Contd..9) 72
Number of Products under Development by Companies, H1 2014 (Contd..10) 73
Number of Products under Development by Companies, H1 2014 (Contd..11) 74
Number of Products under Development by Companies, H1 2014 (Contd..12) 75
Number of Products under Development by Companies, H1 2014 (Contd..13) 76
Number of Products under Investigation by Universities/Institutes, H1 2014 78
Number of Products under Investigation by Universities/Institutes, H1 2014 (Contd..1) 79
Comparative Analysis by Late Stage Development, H1 2014 80
Comparative Analysis by Clinical Stage Development, H1 2014 81
Comparative Analysis by Early Stage Development, H1 2014 82
Comparative Analysis by Unknown Stage Development, H1 2014 83
Products under Development by Companies, H1 2014 84
Products under Development by Companies, H1 2014 (Contd..1) 85
Products under Development by Companies, H1 2014 (Contd..2) 86
Products under Development by Companies, H1 2014 (Contd..3) 87
Products under Development by Companies, H1 2014 (Contd..4) 88
Products under Development by Companies, H1 2014 (Contd..5) 89
Products under Development by Companies, H1 2014 (Contd..6) 90
Products under Development by Companies, H1 2014 (Contd..7) 91
Products under Development by Companies, H1 2014 (Contd..8) 92
Products under Development by Companies, H1 2014 (Contd..9) 93
Products under Development by Companies, H1 2014 (Contd..10) 94
Products under Development by Companies, H1 2014 (Contd..11) 95
Products under Development by Companies, H1 2014 (Contd..12) 96
Products under Development by Companies, H1 2014 (Contd..13) 97
Products under Development by Companies, H1 2014 (Contd..14) 98
Products under Development by Companies, H1 2014 (Contd..15) 99
Products under Development by Companies, H1 2014 (Contd..16) 100
Products under Development by Companies, H1 2014 (Contd..17) 101
Products under Development by Companies, H1 2014 (Contd..18) 102
Products under Development by Companies, H1 2014 (Contd..19) 103
Products under Development by Companies, H1 2014 (Contd..20) 104
Products under Development by Companies, H1 2014 (Contd..21) 105
Products under Development by Companies, H1 2014 (Contd..22) 106
Products under Development by Companies, H1 2014 (Contd..23) 107
Products under Development by Companies, H1 2014 (Contd..24) 108
Products under Development by Companies, H1 2014 (Contd..25) 109
Products under Development by Companies, H1 2014 (Contd..26) 110
Products under Development by Companies, H1 2014 (Contd..27) 111
Products under Investigation by Universities/Institutes, H1 2014 112
Products under Investigation by Universities/Institutes, H1 2014 (Contd..1) 113
Type 2 Diabetes - Pipeline by Bristol-Myers Squibb Company, H1 2014 114
Type 2 Diabetes - Pipeline by Johnson & Johnson, H1 2014 115
Type 2 Diabetes - Pipeline by Boehringer Ingelheim GmbH, H1 2014 116
Type 2 Diabetes - Pipeline by F. Hoffmann-La Roche Ltd., H1 2014 117
Type 2 Diabetes - Pipeline by Shionogi & Co., Ltd., H1 2014 118
Type 2 Diabetes - Pipeline by Amgen Inc., H1 2014 119
Type 2 Diabetes - Pipeline by Sanofi, H1 2014 120
Type 2 Diabetes - Pipeline by AstraZeneca PLC, H1 2014 121
Type 2 Diabetes - Pipeline by Eli Lilly and Company, H1 2014 122
Type 2 Diabetes - Pipeline by GlaxoSmithKline plc, H1 2014 123
Type 2 Diabetes - Pipeline by MedImmune, LLC, H1 2014 124
Type 2 Diabetes - Pipeline by Isis Pharmaceuticals, Inc., H1 2014 125
Type 2 Diabetes - Pipeline by Gilead Sciences, Inc., H1 2014 126
Type 2 Diabetes - Pipeline by Daiichi Sankyo Company, Limited, H1 2014 127
Type 2 Diabetes - Pipeline by Merck & Co., Inc., H1 2014 128
Type 2 Diabetes - Pipeline by Dainippon Sumitomo Pharma Co., Ltd., H1 2014 129
Type 2 Diabetes - Pipeline by Taisho Pharmaceutical Co., Ltd., H1 2014 130
Type 2 Diabetes - Pipeline by Euroscreen S.A., H1 2014 131
Type 2 Diabetes - Pipeline by Novo Nordisk A/S, H1 2014 132
Type 2 Diabetes - Pipeline by Generex Biotechnology Corporation, H1 2014 133
Type 2 Diabetes - Pipeline by Takeda Pharmaceutical Company Limited, H1 2014 134
Type 2 Diabetes - Pipeline by FibroGen, Inc., H1 2014 135
Type 2 Diabetes - Pipeline by Ipsen S.A., H1 2014 136
Type 2 Diabetes - Pipeline by Piramal Enterprises Limited, H1 2014 137
Type 2 Diabetes - Pipeline by Neurocrine Biosciences, Inc., H1 2014 138
Type 2 Diabetes - Pipeline by Teijin Pharma Limited, H1 2014 139
Type 2 Diabetes - Pipeline by Novartis AG, H1 2014 140
Type 2 Diabetes - Pipeline by Astellas Pharma Inc., H1 2014 141
Type 2 Diabetes - Pipeline by Chugai Pharmaceutical Co., Ltd., H1 2014 142
Type 2 Diabetes - Pipeline by Forest Laboratories, Inc., H1 2014 143
Type 2 Diabetes - Pipeline by Glenmark Pharmaceuticals Ltd., H1 2014 144
Type 2 Diabetes - Pipeline by Japan Tobacco Inc., H1 2014 145
Type 2 Diabetes - Pipeline by Kissei Pharmaceutical Co., Ltd., H1 2014 146
Type 2 Diabetes - Pipeline by Les Laboratoires Servier SAS, H1 2014 147
Type 2 Diabetes - Pipeline by Mitsubishi Tanabe Pharma Corporation, H1 2014 148
Type 2 Diabetes - Pipeline by Pfizer Inc., H1 2014 149
Type 2 Diabetes - Pipeline by Ranbaxy Laboratories Limited, H1 2014 150
Type 2 Diabetes - Pipeline by Zydus Cadila Healthcare Limited, H1 2014 151
Type 2 Diabetes - Pipeline by Hadasit Medical Research Services & Development Ltd, H1 2014 152
Type 2 Diabetes - Pipeline by Biodel Inc., H1 2014 153
Type 2 Diabetes - Pipeline by Bayer AG, H1 2014 154
Type 2 Diabetes - Pipeline by OPKO Health, Inc., H1 2014 155
Type 2 Diabetes - Pipeline by MannKind Corporation, H1 2014 156
Type 2 Diabetes - Pipeline by Halozyme Therapeutics, Inc., H1 2014 157
Type 2 Diabetes - Pipeline by Toray Industries, Inc., H1 2014 158
Type 2 Diabetes - Pipeline by Merck KGaA, H1 2014 159
Type 2 Diabetes - Pipeline by Alchemia Limited, H1 2014 160
Type 2 Diabetes - Pipeline by Addex Therapeutics, H1 2014 161
Type 2 Diabetes - Pipeline by Evotec AG, H1 2014 162
Type 2 Diabetes - Pipeline by AlbireoPharma, H1 2014 163
Type 2 Diabetes - Pipeline by GW Pharmaceuticals plc, H1 2014 164
Type 2 Diabetes - Pipeline by Harbor Therapeutics, Inc., H1 2014 165
Type 2 Diabetes - Pipeline by Enzo Biochem, Inc., H1 2014 166
Type 2 Diabetes - Pipeline by Genfit SA, H1 2014 167
Type 2 Diabetes - Pipeline by Ligand Pharmaceuticals, Inc., H1 2014 168
Type 2 Diabetes - Pipeline by Mesoblast Limited, H1 2014 169
Type 2 Diabetes - Pipeline by Oramed Pharmaceuticals, Inc., H1 2014 170
Type 2 Diabetes - Pipeline by Orchid Chemicals & Pharmaceuticals Ltd, H1 2014 171
Type 2 Diabetes - Pipeline by ConjuChem Biotechnologies Inc., H1 2014 172
Type 2 Diabetes - Pipeline by Lexicon Pharmaceuticals, Inc., H1 2014 173
Type 2 Diabetes - Pipeline by Arena Pharmaceuticals, Inc., H1 2014 174
Type 2 Diabetes - Pipeline by Flamel Technologies S.A., H1 2014 175
Type 2 Diabetes - Pipeline by CSL Limited, H1 2014 176
Type 2 Diabetes - Pipeline by ProteoTech, Inc., H1 2014 177
Type 2 Diabetes - Pipeline by Sanwa Kagaku Kenkyusho Co., Ltd., H1 2014 178
Type 2 Diabetes - Pipeline by Yuhan Corporation, H1 2014 179
Type 2 Diabetes - Pipeline by XOMA Corporation, H1 2014 180
Type 2 Diabetes - Pipeline by Immuron Limited, H1 2014 181
Type 2 Diabetes - Pipeline by IPCA Laboratories Limited, H1 2014 182
Type 2 Diabetes - Pipeline by Xenetic Biosciences plc, H1 2014 183
Type 2 Diabetes - Pipeline by Handok Inc., H1 2014 184
Type 2 Diabetes - Pipeline by Hyundai Pharmaceutical Co., Ltd., H1 2014 185
Type 2 Diabetes - Pipeline by LG Life Sciences, Ltd., H1 2014 186
Type 2 Diabetes - Pipeline by Transition Therapeutics Inc., H1 2014 187
Type 2 Diabetes - Pipeline by Jiangsu Hengrui Medicine Co., Ltd., H1 2014 188
Type 2 Diabetes - Pipeline by Uni-Bio Science Group Ltd., H1 2014 189
Type 2 Diabetes - Pipeline by Panacea Biotec Limited, H1 2014 190
Type 2 Diabetes - Pipeline by Summit Corporation plc, H1 2014 191
Type 2 Diabetes - Pipeline by Phynova Group Ltd, H1 2014 192
Type 2 Diabetes - Pipeline by Genovate Biotechnology Co., LTD., H1 2014 193
Type 2 Diabetes - Pipeline by DiaMedica Inc., H1 2014 194
Type 2 Diabetes - Pipeline by NeuroVive Pharmaceutical AB, H1 2014 195
Type 2 Diabetes - Pipeline by Angelini Group, H1 2014 196
Type 2 Diabetes - Pipeline by Debiopharm International S.A., H1 2014 197
Type 2 Diabetes - Pipeline by Advinus Therapeutics Ltd., H1 2014 198
Type 2 Diabetes - Pipeline by CJ CheilJedang Corp., H1 2014 199
Type 2 Diabetes - Pipeline by Chipscreen Biosciences Ltd, H1 2014 200
Type 2 Diabetes - Pipeline by Aurigene Discovery Technologies Limited, H1 2014 201
Type 2 Diabetes - Pipeline by ActogeniX NV, H1 2014 202
Type 2 Diabetes - Pipeline by Camurus AB, H1 2014 203
Type 2 Diabetes - Pipeline by Jenrin Discovery, Inc., H1 2014 204
Type 2 Diabetes - Pipeline by reMYND, H1 2014 205
Type 2 Diabetes - Pipeline by Wellstat Therapeutics Corporation, H1 2014 206
Type 2 Diabetes - Pipeline by Celon Pharma Sp. z o.o., H1 2014 207
Type 2 Diabetes - Pipeline by Cortendo Invest AB, H1 2014 208
Type 2 Diabetes - Pipeline by Anchor Therapeutics, Inc., H1 2014 209
Type 2 Diabetes - Pipeline by Arisaph Pharmaceuticals, Inc., H1 2014 210
Type 2 Diabetes - Pipeline by Protemix Corporation Limited, H1 2014 211
Type 2 Diabetes - Pipeline by Allozyne, Inc., H1 2014 212
Type 2 Diabetes - Pipeline by Metabolic Solutions Development Co., H1 2014 213
Type 2 Diabetes - Pipeline by Zafgen Inc., H1 2014 214
Type 2 Diabetes - Pipeline by Catabasis Pharmaceuticals, Inc., H1 2014 215
Type 2 Diabetes - Pipeline by PhaseBio Pharmaceuticals, Inc., H1 2014 216
Type 2 Diabetes - Pipeline by Melior Discovery, Inc., H1 2014 217
Type 2 Diabetes - Pipeline by Diabetology Limited, H1 2014 218
Type 2 Diabetes - Pipeline by Braasch Biotech LLC, H1 2014 219
Type 2 Diabetes - Pipeline by Zealand Pharma A/S, H1 2014 220
Type 2 Diabetes - Pipeline by Intarcia Therapeutics, Inc., H1 2014 221
Type 2 Diabetes - Pipeline by Theracos, Inc., H1 2014 222
Type 2 Diabetes - Pipeline by Versartis, Inc., H1 2014 223
Type 2 Diabetes - Pipeline by Kainos Medicine, Inc., H1 2014 224
Type 2 Diabetes - Pipeline by Nordic Bioscience a/s, H1 2014 225
Type 2 Diabetes - Pipeline by InteKrin Therapeutics, Inc., H1 2014 226
Type 2 Diabetes - Pipeline by Virobay Inc., H1 2014 227
Type 2 Diabetes - Pipeline by Noxxon Pharma AG, H1 2014 228
Type 2 Diabetes - Pipeline by Avaxia Biologics, Inc., H1 2014 229
Type 2 Diabetes - Pipeline by Intercept Pharmaceuticals, Inc., H1 2014 230
Type 2 Diabetes - Pipeline by Omeros Corporation, H1 2014 231
Type 2 Diabetes - Pipeline by TransTech Pharma, Inc., H1 2014 232
Type 2 Diabetes - Pipeline by Bridge Bioresearch Plc, H1 2014 233
Type 2 Diabetes - Pipeline by Synthetic Biologics, Inc., H1 2014 234
Type 2 Diabetes - Pipeline by Targacept, Inc., H1 2014 235
Type 2 Diabetes - Pipeline by N-Gene Research Laboratories, Inc., H1 2014 236
Type 2 Diabetes - Pipeline by Obio Pharmaceutical Holdings Limited, H1 2014 237
Type 2 Diabetes - Pipeline by ChemoCentryx, Inc., H1 2014 238
Type 2 Diabetes - Pipeline by USV Limited, H1 2014 239
Type 2 Diabetes - Pipeline by Vitae Pharmaceuticals, Inc., H1 2014 240
Type 2 Diabetes - Pipeline by CureDM, Inc., H1 2014 241
Type 2 Diabetes - Pipeline by Verva Pharmaceuticals Limited, H1 2014 242
Type 2 Diabetes - Pipeline by Exsulin Corporation, H1 2014 243
Type 2 Diabetes - Pipeline by Medestea Research & Production S.p.A., H1 2014 244
Type 2 Diabetes - Pipeline by NasVax Ltd., H1 2014 245
Type 2 Diabetes - Pipeline by Stelic Institute & Co., H1 2014 246
Type 2 Diabetes - Pipeline by Vybion, Inc., H1 2014 247
Type 2 Diabetes - Pipeline by Regulus Therapeutics Inc., H1 2014 248
Type 2 Diabetes - Pipeline by Esperion Therapeutics, Inc., H1 2014 249
Type 2 Diabetes - Pipeline by Sihuan Pharmaceutical Holdings Group Ltd., H1 2014 250
Type 2 Diabetes - Pipeline by NGM Biopharmaceuticals, Inc., H1 2014 251
Type 2 Diabetes - Pipeline by Alize Pharma SAS, H1 2014 252
Type 2 Diabetes - Pipeline by Ardelyx, Inc., H1 2014 253
Type 2 Diabetes - Pipeline by Heptares Therapeutics Ltd., H1 2014 254
Type 2 Diabetes - Pipeline by Mitsubishi Pharmaceutical Corporation, H1 2014 255
Type 2 Diabetes - Pipeline by Receptos, Inc., H1 2014 256
Type 2 Diabetes - Pipeline by MicroDose Therapeutx, Inc., H1 2014 257
Type 2 Diabetes - Pipeline by Sirona Biochem Corp, H1 2014 258
Type 2 Diabetes - Pipeline by XBiotech USA, Inc., H1 2014 259
Type 2 Diabetes - Pipeline by Carmot Therapeutics, Inc., H1 2014 260
Type 2 Diabetes - Pipeline by Connexios Life Sciences Pvt. Ltd., H1 2014 261
Type 2 Diabetes - Pipeline by Serometrix, LLC, H1 2014 262
Type 2 Diabetes - Pipeline by PharmaIN Corporation, H1 2014 263
Type 2 Diabetes - Pipeline by Stempeutics Research Private Limited, H1 2014 264
Type 2 Diabetes - Pipeline by Serodus ASA, H1 2014 265
Type 2 Diabetes - Pipeline by SignPath Pharma Inc, H1 2014 266
Type 2 Diabetes - Pipeline by Elcelyx Therapeutics, Inc., H1 2014 267
Type 2 Diabetes - Pipeline by Thermalin Diabetes Inc., H1 2014 268
Type 2 Diabetes - Pipeline by Selvita S.A, H1 2014 269
Type 2 Diabetes - Pipeline by Poxel SA, H1 2014 270
Type 2 Diabetes - Pipeline by Medesis Pharma S.A., H1 2014 271
Type 2 Diabetes - Pipeline by Kadmon Pharmaceuticals, LLC, H1 2014 272
Type 2 Diabetes - Pipeline by Neopharm Co., Ltd., H1 2014 273
Type 2 Diabetes - Pipeline by Shanghai Pharmaceuticals Holding Co Ltd, H1 2014 274
Type 2 Diabetes - Pipeline by Hanmi Pharmaceuticals, Co. Ltd., H1 2014 275
Type 2 Diabetes - Pipeline by Metabolys S.A.S., H1 2014 276
Type 2 Diabetes - Pipeline by Boston Therapeutics, Inc., H1 2014 277
Type 2 Diabetes - Pipeline by Cardiolynx AG, H1 2014 278
Type 2 Diabetes - Pipeline by TWi Pharmaceuticals, Inc., H1 2014 279
Type 2 Diabetes - Pipeline by Allinky Biopharma, H1 2014 280
Type 2 Diabetes - Pipeline by Rhizen Pharmaceuticals SA, H1 2014 281
Type 2 Diabetes - Pipeline by Hua Medicine Ltd., H1 2014 282
Type 2 Diabetes - Pipeline by Curaxys, S.L., H1 2014 283
Type 2 Diabetes - Pipeline by MidaSol Therapeutics LP, H1 2014 284
Type 2 Diabetes - Pipeline by Foresee Pharmaceuticals, LLC, H1 2014 285
Type 2 Diabetes - Pipeline by Paras Biopharmaceuticals Finland Oy, H1 2014 286
Type 2 Diabetes - Pipeline by CymaBay Therapeutics, Inc., H1 2014 287
Type 2 Diabetes - Pipeline by Biospherics.net Incorporated, H1 2014 288
Type 2 Diabetes - Pipeline by Dong-A Socio Holdings Co Ltd, H1 2014 289
Assessment by Monotherapy Products, H1 2014 290
Assessment by Combination Products, H1 2014 291
Number of Products by Stage and Target, H1 2014 294
Number of Products by Stage and Mechanism of Action, H1 2014 303
Number of Products by Stage and Route of Administration, H1 2014 313
Number of Products by Stage and Molecule Type, H1 2014 316
Type 2 Diabetes Therapeutics - Recent Pipeline Updates, H1 2014 932
Type 2 Diabetes - Dormant Projects, H1 2014 1034
Type 2 Diabetes - Discontinued Products, H1 2014 1040
List of Figures
Number of Products under Development for Type 2 Diabetes, H1 2014 60
Number of Products under Development for Type 2 Diabetes - Comparative Analysis, H1 2014 61
Number of Products under Development by Companies, H1 2014 62
Number of Products under Investigation by Universities/Institutes, H1 2014 77
Comparative Analysis by Late Stage Development, H1 2014 80
Comparative Analysis by Clinical Stage Development, H1 2014 81
Comparative Analysis by Early Stage Products, H1 2014 82
Assessment by Monotherapy Products, H1 2014 290
Assessment by Combination Products, H1 2014 291
Number of Products by Top 10 Target, H1 2014 292
Number of Products by Stage and Top 10 Target, H1 2014 293
Number of Products by Top 10 Mechanism of Action, H1 2014 301
Number of Products by Stage and Top 10 Mechanism of Action, H1 2014 302
Number of Products by Top 10 Route of Administration, H1 2014 311
Number of Products by Stage and Top 10 Route of Administration, H1 2014 312
Number of Products by Top 10 Molecule Type, H1 2014 314
Number of Products by Stage and Top 10 Molecule Type, H1 2014 315
